In the MPTP monkey model of PD, intrathecal delivery of human recombinant BDNF before and in parallel to MPTP injection attenuates PD symptom progression, which correlates with reduced SN dopaminergic cell degeneration compared to animals without exogenously applied BDNF [145]. This evidence concerns the gene BDNF and Parkinson disease.